Physician profile
John Kim
NPI 1194388736
$6,387.07
in general payments reported to CMS, 2019-2025
42 companies · $1,394 in 2025
The $1,394 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $198 · 2023: $1,179 · 2024: $3,615 · 2025: $1,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,868 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,750 · Travel and Lodging: $323 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,867.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,750.00 |
| Travel and Lodging | $323.41 |
| Education | $247.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $2,750.00 | 2024 | Brukinsa |
| Incyte Corporation | $580.37 | 2022-2025 | Jakafi, Monjuvi, Niktimvo |
| Medshape, INC. | $323.41 | 2023 | Dynanail |
| Sanofi-Aventis U.S. LLC | $204.27 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $198.87 | 2023-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals Lp | $154.46 | 2022-2025 | Enhertu, Imfinzi, Fasenra |
| Trilliant Surgical LLC. | $140.81 | 2023 | Arsenal Ankle 10 Hole 1/3 Tubular Plate |
| Janssen Biotech, INC. | $137.70 | 2024-2025 | Rybrevant, Carvykti, Erleada |
| Genmab U.S., INC. | $136.41 | 2023-2025 | Epkinly |
| Rigel Pharmaceuticals, INC. | $123.41 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Adc Therapeutics America, INC. | $123.31 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $119.33 | 2023-2025 | Libtayo |
| Sobi, INC | $111.29 | 2023-2024 | |
| Morphosys, US INC. | $97.68 | 2023 | Monjuvi |
| Genzyme Corporation | $95.38 | 2024-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.